Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell cycle effects of CC-1065.

B K Bhuyan, S L Crampton, E G Adams

    Cancer Research
    |September 1, 1983
    PubMed
    Summary

    CC-1065 is a potent antitumor agent that inhibits DNA synthesis and kills cancer cells. It is most toxic to mitotic cells and blocks cell progression in the S and G2 phases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Multiple, unilateral lisch nodules in the absence of other manifestations of neurofibromatosis type 1.

    Case reports in ophthalmological medicine·2012
    Same author

    Proinflammatory cytokine and human immunodeficiency virus RNA levels during early Mycobacterium avium complex bacteremia in advanced AIDS.

    The Journal of infectious diseases·1998
    Same author

    Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays.

    Cancer chemotherapy and pharmacology·1997
    Same author

    Differential expression of dystrophin isoforms in strains of mdx mice with different mutations.

    Human molecular genetics·1996
    Same author

    Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.

    Cancer chemotherapy and pharmacology·1995
    Same author

    V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant.

    Cancer chemotherapy and pharmacology·1994

    Area of Science:

    • Pharmacology
    • Molecular Biology
    • Cancer Research

    Background:

    • CC-1065 demonstrates significant antitumor activity in laboratory settings.
    • The drug's mechanism involves inhibition of DNA synthesis and binding to DNA.
    • Understanding its kinetic and cell-cycle-specific effects is crucial for therapeutic development.

    Purpose of the Study:

    • To investigate the kinetics of DNA synthesis inhibition by CC-1065.
    • To determine the cell-cycle-specific toxicity of CC-1065.
    • To analyze the effects of CC-1065 on cell progression through different phases of the cell cycle.

    Main Methods:

    • Synchronized Chinese Hamster Ovary (CHO) and B16 melanoma cell cultures were used.
    • Colcemid pretreatment was employed to obtain mitotic cells for toxicity studies.
    • Cell progression and DNA synthesis inhibition were monitored over time after CC-1065 exposure.

    Main Results:

    • Mitotic cells exhibited the highest sensitivity to CC-1065, with sensitivity decreasing in G1, S, and G2 phases.
    • CC-1065 did not impede progression from mitosis to G1 or G1 to S.
    • Drug exposure led to slow progression through S phase at low concentrations and a block at higher concentrations, with a complete block in G2 to M progression.

    Conclusions:

    • CC-1065 exhibits potent dose-dependent inhibition of DNA synthesis and cell cycle progression.
    • The drug's phase-specific toxicity, with maximal effect on mitotic cells, is a key characteristic.
    • CC-1065 represents a promising antitumor agent with a distinct mechanism of action impacting DNA synthesis and cell cycle progression.

    Related Experiment Videos